Covidien (COV) - FREE Research Report

Almeida Jose E who is President and Chief Executive at COVIDIEN sold 979 shares at $57.41 per share for a total value of $56,204.39 on July 1, 2013. Following this transaction, the President and Chief Executive owned 212,478 shares meaning that the stake was reduced by 0.46% with the 979 share sell-off.

Hanson Bryan C who is Senior Vice President at COVIDIEN sold 224 shares at $57.41 per share for a total value of $12,859.84 on July 1, 2013. Following this transaction, the Senior Vice President owned 21,741 shares meaning that the stake was reduced by 1.02% with the 224 share sell-off.

Sgrignari Michael who is Senior Vice President at COVIDIEN sold 53 shares at $57.41 per share for a total value of $3,042.73 on July 1, 2013. Following this transaction, the Senior Vice President owned 22,096 shares meaning that the stake was reduced by 0.24% with the 53 share sell-off.

Wehrly Peter L who is Senior Vice President at COVIDIEN sold 273 shares at $57.41 per share for a total value of $15,672.93 on July 1, 2013. Following this transaction, the Senior Vice President owned 24,985 shares meaning that the stake was reduced by 1.08% with the 273 share sell-off.

The shares most recently traded at $57.76, up $0.64, or 1.12% since the insider transactions. Historical insider transactions for Covidien go as follows:

  • 4-Week # shares sold: 2,652
  • 12-Week # shares sold: 19,180
  • 24-Week # shares sold: 29,180

The average volume for Covidien has been 3.3 million shares per day over the past 30 days. Covidien has a market cap of $27.0 billion and is part of the health care sector and health services industry. Shares are down 0.57% year to date as of the close of trading on Tuesday.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The stock currently has a dividend yield of 1.81%. The company has a P/E ratio of 14.9. Currently there are 14 analysts that rate Covidien a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on COV - FREE

TheStreet Quant Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Covidien Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Aqua America: Go With the Flow

4 Stocks Poised for Profitable Trades

4 Market Segments to Avoid

Aqua America (WTR) Reaches New Lifetime High Today

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan